These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11460845)

  • 21. Aspirin for primary prevention in patients with diabetes mellitus.
    Nguyen KX; Marinac JS; Sun C
    Fam Med; 2005 Feb; 37(2):112-7. PubMed ID: 15690251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
    Berger JS; Brown DL; Becker RC
    Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Don't use aspirin for primary prevention of cardiovascular disease.
    Barnett H; Burrill P; Iheanacho I
    BMJ; 2010 Apr; 340():c1805. PubMed ID: 20410163
    [No Abstract]   [Full Text] [Related]  

  • 24. A review of vitamins A, C, and E and their relationship to cardiovascular disease.
    Brown DJ; Goodman J
    Clin Excell Nurse Pract; 1998 Jan; 2(1):10-22. PubMed ID: 12675072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin E and cardiovascular disease: observational studies.
    Gaziano JM
    Ann N Y Acad Sci; 2004 Dec; 1031():280-91. PubMed ID: 15753154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antioxidant vitamin supplementation in cardiovascular diseases.
    Riccioni G; Bucciarelli T; Mancini B; Corradi F; Di Ilio C; Mattei PA; D'Orazio N
    Ann Clin Lab Sci; 2007; 37(1):89-95. PubMed ID: 17311876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials with vitamin E in cardiovascular disease: are they meaningful?
    Violi F; Micheletta F; Iuliano L
    Thromb Haemost; 2001 Oct; 86(4):1121-2. PubMed ID: 11686337
    [No Abstract]   [Full Text] [Related]  

  • 30. Aspirin for primary prevention of cardiovascular disease (revisited).
    Med Lett Drugs Ther; 2006 Jul; 48(1238):53. PubMed ID: 16841021
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of vitamin E in the prevention of cardiovascular disease and cancer.
    Punnam SR
    JAMA; 2005 Nov; 294(19):2432; author reply 2432. PubMed ID: 16287949
    [No Abstract]   [Full Text] [Related]  

  • 32. [Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project].
    Nordt T
    Internist (Berl); 2001 Dec; 42(12):1705-7. PubMed ID: 11793610
    [No Abstract]   [Full Text] [Related]  

  • 33. Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial.
    Marchioli R; Levantesi G; Macchia A; Marfisi RM; Nicolosi GL; Tavazzi L; Tognoni G; Valagussa F;
    J Cardiovasc Med (Hagerstown); 2006 May; 7(5):347-50. PubMed ID: 16645413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin E and cardiovascular disease.
    Marchioli R
    Thromb Haemost; 2001 May; 85(5):758-60. PubMed ID: 11372663
    [No Abstract]   [Full Text] [Related]  

  • 35. [Results of GISSI Prevenzione: diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione].
    Marchioli R
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):745-6. PubMed ID: 12503535
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease.
    Eidelman RS; Hollar D; Hebert PR; Lamas GA; Hennekens CH
    Arch Intern Med; 2004 Jul; 164(14):1552-6. PubMed ID: 15277288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice.
    Antoniades C; Tousoulis D; Tentolouris C; Toutouzas P; Stefanadis C
    Herz; 2003 Nov; 28(7):628-38. PubMed ID: 14689123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    Laine L
    Aliment Pharmacol Ther; 2006 Sep; 24(6):897-908. PubMed ID: 16948802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin E supplementation in cardiovascular disease and cancer prevention: Part 1.
    Pham DQ; Plakogiannis R
    Ann Pharmacother; 2005 Nov; 39(11):1870-8. PubMed ID: 16189282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.